WO2007089870A3 - Vaccine delivery compositions and methods of use - Google Patents

Vaccine delivery compositions and methods of use Download PDF

Info

Publication number
WO2007089870A3
WO2007089870A3 PCT/US2007/002704 US2007002704W WO2007089870A3 WO 2007089870 A3 WO2007089870 A3 WO 2007089870A3 US 2007002704 W US2007002704 W US 2007002704W WO 2007089870 A3 WO2007089870 A3 WO 2007089870A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
polyester
tumor cells
organism
immunostimulatory
Prior art date
Application number
PCT/US2007/002704
Other languages
French (fr)
Other versions
WO2007089870A2 (en
Inventor
William Turnell
Kristin Defife
Maria A Vitiello
Original Assignee
Medivas Llc
William Turnell
Kristin Defife
Maria A Vitiello
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/344,689 external-priority patent/US20060177416A1/en
Priority claimed from PCT/US2006/003575 external-priority patent/WO2006088647A1/en
Priority claimed from US11/345,021 external-priority patent/US20060188469A1/en
Priority claimed from PCT/US2006/003412 external-priority patent/WO2006083874A2/en
Priority claimed from US11/345,815 external-priority patent/US20060188486A1/en
Priority claimed from US11/636,230 external-priority patent/US20070160622A1/en
Application filed by Medivas Llc, William Turnell, Kristin Defife, Maria A Vitiello filed Critical Medivas Llc
Priority to EP07762672A priority Critical patent/EP1986685A4/en
Priority to CA002676601A priority patent/CA2676601A1/en
Priority to JP2008553341A priority patent/JP2009525341A/en
Publication of WO2007089870A2 publication Critical patent/WO2007089870A2/en
Publication of WO2007089870A3 publication Critical patent/WO2007089870A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides synthetic vaccines against a variety of pathogenic organisms and tumor cells in humans and other mammals based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants. The vaccines can be formulated as a liquid dispersion of polymer particles or molecules in which are dispersed an immunostimulatory adjuvant, such as a TLR agonist, and whole protein or peptidic antigens containing MHC class I or class II epitopes derived from organism or tumor cell proteins. Methods of inducing an immune response via intracellular mechanisms to the pathogenic organism or tumor cells specific for the antigen in the invention compositions are also included.
PCT/US2007/002704 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use WO2007089870A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07762672A EP1986685A4 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use
CA002676601A CA2676601A1 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use
JP2008553341A JP2009525341A (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
USPCT/US2006/003412 2006-01-31
US11/344,689 US20060177416A1 (en) 2003-10-14 2006-01-31 Polymer particle delivery compositions and methods of use
US11/344,689 2006-01-31
PCT/US2006/003575 WO2006088647A1 (en) 2005-02-17 2006-01-31 Polymer particle delivery compositions and methods of use
US11/345,021 2006-01-31
USPCT/US2006/003575 2006-01-31
US11/345,021 US20060188469A1 (en) 2003-10-14 2006-01-31 Vaccine delivery compositions and methods of use
PCT/US2006/003412 WO2006083874A2 (en) 2005-02-01 2006-01-31 Vaccine delivery compositions and methods of use
US11/345,815 US20060188486A1 (en) 2003-10-14 2006-02-01 Wound care polymer compositions and methods for use thereof
US11/345,815 2006-02-01
US84242306P 2006-09-05 2006-09-05
US60/842,423 2006-09-05
US85817306P 2006-11-10 2006-11-10
US60/858,173 2006-11-10
US11/636,230 2006-12-07
US11/636,230 US20070160622A1 (en) 2005-12-07 2006-12-07 Method for assembling a polymer-biologic delivery composition

Publications (2)

Publication Number Publication Date
WO2007089870A2 WO2007089870A2 (en) 2007-08-09
WO2007089870A3 true WO2007089870A3 (en) 2008-05-02

Family

ID=56290916

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/002704 WO2007089870A2 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use

Country Status (4)

Country Link
EP (1) EP1986685A4 (en)
JP (1) JP2009525341A (en)
CA (1) CA2676601A1 (en)
WO (1) WO2007089870A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US9517203B2 (en) 2000-08-30 2016-12-13 Mediv As, Llc Polymer particle delivery compositions and methods of use

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445007B2 (en) 2005-09-22 2013-05-21 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
US8067237B2 (en) 2005-12-13 2011-11-29 President And Fellows Of Harvard College Scaffolds for cell transplantation
WO2009102465A2 (en) * 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
EP2421561A2 (en) * 2009-04-21 2012-02-29 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
US8629151B2 (en) * 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
EP2575773A4 (en) 2010-05-26 2014-06-25 Selecta Biosciences Inc Synthetic nanocarrier combination vaccines
EP2575869B1 (en) * 2010-06-04 2017-07-26 Flow Pharma Inc. Peptide particle formulation
AU2011311904B2 (en) 2010-10-06 2016-02-25 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
EP3159368B1 (en) 2011-06-23 2024-07-24 DSM IP Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN103702687A (en) 2011-07-29 2014-04-02 西莱克塔生物科技公司 Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
DK2838515T3 (en) 2012-04-16 2020-02-24 Harvard College MESOPOROUS SILICON Dioxide COMPOSITIONS FOR MODULATING IMMUNE RESPONSES
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
CN107106509B (en) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 Drug delivery system for delivering acid sensitive drugs
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (en) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Immune cell capture device and its manufacture and use
DE102015109996B3 (en) * 2015-06-22 2016-07-28 Gerresheimer Regensburg Gmbh Device for opening capsules
CN115531609A (en) 2016-02-06 2022-12-30 哈佛学院校长同事会 Remodeling hematopoietic niches to reconstitute immunity
EP3484448A4 (en) 2016-07-13 2020-04-01 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
KR20240054289A (en) * 2021-08-30 2024-04-25 도레이 카부시키가이샤 Composition for enhancing immunogenicity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061916A1 (en) * 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US20060002947A1 (en) * 1999-09-14 2006-01-05 Robert Humphreys Ii-key/antigenic epitope hybrid peptide vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188469A1 (en) * 2003-10-14 2006-08-24 Medivas, Llc Vaccine delivery compositions and methods of use
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
KR20070101341A (en) * 2005-02-01 2007-10-16 메디바스, 엘엘씨 Vaccine delivery compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061916A1 (en) * 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
US20060002947A1 (en) * 1999-09-14 2006-01-05 Robert Humphreys Ii-key/antigenic epitope hybrid peptide vaccines
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517203B2 (en) 2000-08-30 2016-12-13 Mediv As, Llc Polymer particle delivery compositions and methods of use
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof

Also Published As

Publication number Publication date
JP2009525341A (en) 2009-07-09
WO2007089870A2 (en) 2007-08-09
CA2676601A1 (en) 2007-08-09
EP1986685A2 (en) 2008-11-05
EP1986685A4 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
WO2007089870A3 (en) Vaccine delivery compositions and methods of use
WO2006083874A3 (en) Vaccine delivery compositions and methods of use
Kumar et al. Bacterial protein toll-like-receptor agonists: a novel perspective on vaccine adjuvants
US20240307518A1 (en) Subunit vaccine delivery platform for robust humoral and cellular immune responses
AR121383A2 (en) PEPTIDES AND PEPTIDE COMBINATION AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCER
ES2924027T3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
Rosenthal et al. Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles
WO2009079564A3 (en) Immunogenic compositions and methods of use thereof
IL189313A0 (en) Virus-like particles as vaccines for paramyxovirus
HK1220709A1 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules (hla)ii
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
WO2005099752A3 (en) Antigen delivery vectors and constructs
ATE494303T1 (en) TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND ASSOCIATED CANCER VACCINE
CN106421743A (en) Polymer particles and uses thereof
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
TR200103333T2 (en) Auxiliary drug (SBA) that improves endurance and biological compatibility
DE602006012328D1 (en) BIFUNCTIONAL PROTEIN ANCHOR
UA97092C2 (en) T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
EA200900738A1 (en) SLIP PROTEINS CONTAINING ANTIGENS OF TUMOR TENSIONS NY-ESO-1 AND LAGE-1
EA200701440A1 (en) COMPOSITIONS FOR IMMUNIZATION AGAINST MYCOBACTERIA
ATE435660T1 (en) IMMUNOGENIC POLYPEPTIDE CONSISTING OF OPTIMIZED CRYPTIC PEPTIDES FROM TUMOR ANTIGENS AND ITS USES
Rubio‐Reyes et al. Immunological properties and protective efficacy of a single mycobacterial antigen displayed on polyhydroxybutyrate beads
CN107417773B (en) Cell wall binding peptides
WO2006105168A3 (en) Enhancing immune responses with bacterial exotoxins
RU2008131066A (en) PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN NMA0939

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008553341

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007762672

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2676601

Country of ref document: CA